Physician profile
Krishma Zaver
NPI 1215500566
$4,347.57
in general payments reported to CMS, 2019-2025
18 companies · $933 in 2025
The $933 reported for 2025 was more than what 90% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $199 · 2022: $1,415 · 2023: $943 · 2024: $858 · 2025: $933.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,734.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,733.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $705.18 | 2021-2024 | Cequa |
| Abbvie INC. | $599.48 | 2024-2025 | |
| Dompe US, INC. | $425.49 | 2022-2025 | Oxervate |
| Sight Sciences, INC. | $318.03 | 2021-2025 | Tearcare System |
| Coopervision INC. | $305.95 | 2022-2024 | Misight Contact Lens |
| Johnson & Johnson Vision Care, INC. | $281.95 | 2022-2023 | Acuvue |
| Glaukos Corporation | $266.33 | 2021-2023 | |
| Alcon Vision LLC | $244.85 | 2024-2025 | Tryptyr, Rocklatan, Rhopressa |
| Bausch & Lomb Americas INC. | $240.43 | 2022-2024 | Infuse, Miebo |
| Biotissue Holdings INC. | $180.70 | 2023-2025 | |
| Harrow Eye, LLC | $178.09 | 2024 | Vevye |
| Johnson & Johnson Surgical Vision, INC. | $168.31 | 2022-2024 | Tecnis Iol |
| Tarsus Pharmaceuticals, INC. | $116.74 | 2024-2025 | Xdemvy |
| Iridex Corporation | $116.17 | 2023 | |
| Visioneering Technologies, INC. | $83.33 | 2023 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kala Pharmaceuticals, INC. | $52.41 | 2022 | |
| Genzyme Corporation | $50.00 | 2025 | |
| Novartis Pharmaceuticals Corporation | $14.13 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Krishma Zaver listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.